Radiation Oncology

TTFields

Questions discussed in this category

Is it reasonable to extrapolate data from Glioblastoma and discuss Tumor Treating Fields in patients with Grade 4, IDH Mutant, astrocytomas?

2 Answers available

How do you incorporate TTFields into your clinical practice?

Do you routinely recommend TTF in the adjuvant setting for patients with glioblastoma?

5 Answers available

How do you improve compliance with TTFields for patients who would like to discontinue therapy?

4 Answers available

How do you sequence TTFields into your salvage therapy plan for patients with recurrent glioblastoma?

3 Answers available

What is the role for TTFields in patients who cannot undergo complete surgical resection for glioblastoma?

2 Answers available

How do you counsel patients on TTFields if they have reservations about the aesthetics and inconvenience of the treatment?

4 Answers available

What are the common side effects that you observe with TTFields?

How do you manage these?

4 Answers available

Are there particular subgroups of patients with glioblastoma who derive the most benefit from TTFields?

5 Answers available

Papers discussed in this category

JAMA, 2017-12-19

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Journal for immunotherapy of cancer, 2018-11-23

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.

Neuro-oncology, 2016 May 13

The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.

Frontiers in oncology, 2020 Jul 28

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.

Oncology letters, 2019 Nov 19

Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields.

Annals of translational medicine, 2021 Dec

Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma.

Related Topics in Radiation Oncology